Omeros Corporation (OMER)Healthcare | Biotechnology | Seattle, United States | NasdaqGM
13.44 USD
+0.90
(7.177%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 13.21 -0.23 (-0.227%) ⇩ (April 17, 2026, 7:52 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:07 a.m. EDT
Omeros (OMER) presents a classic biotech 're-rating' scenario where strong analyst targets (38.0) and recent earnings/milestone news drive a call-heavy options flow, masking a fundamentally broken balance sheet (negative book value, -0.25 ROA). While short-term momentum leans bullish on a successful Novo deal and drug launch, the lack of dividends and poor fundamentals restrict this to a high-risk momentum play rather than an investment; the data suggests traders are betting on the upside catalysts despite the near-term bearish forecast correction (-0.008%), creating a volatile environment with minimal floor. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.085901 |
| AutoETS | 0.101768 |
| AutoARIMA | 0.108718 |
| AutoTheta | 0.153152 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 55% |
| H-stat | 2.63 |
| Ljung-Box p | 0.001 |
| Jarque-Bera p | 0.284 |
| Excess Kurtosis | 0.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 967,628,480 |
| Forward P/E | 9.76 |
| Beta | 2.53 |
| Website | https://www.omeros.com |
As of April 19, 2026, 12:07 a.m. EDT: Options flow indicates high speculative variance (IV 0.77-10.06%) with a distinct lack of downside hedges. Despite significant Put Open Interest (OI) at deep strikes (e.g., 3.0, 7.0, 8.0), Call volume and OI dominate at 13.0-30.0 strikes, especially for the Apr 17 expiration where Call OI is heavy and 'Top OI' notes appear on strikes 12.0 and 13.0. The deep puts show high IV (13.0) suggesting stale or fear-based positioning, whereas the ATM/Money calls show active volume and 'New Flow'. There is almost no activity beyond 1.0 OMER strike, indicating the market is pricing in a range of roughly 8.0-18.0 within the month, with heavier sentiment favoring the upside or status quo over a crash scenario.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0059702 |
| Address1 | The Omeros Building |
| Address2 | 201 Elliott Avenue West |
| All Time High | 30.23 |
| All Time Low | 0.92 |
| Ask | 13.49 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 1,148,460 |
| Average Daily Volume3 Month | 1,123,625 |
| Average Volume | 1,123,625 |
| Average Volume10Days | 1,148,460 |
| Beta | 2.529 |
| Bid | 13.4 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | -1.691 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.44 |
| Current Ratio | 2.763 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 13.455 |
| Day Low | 12.46 |
| Display Name | Omeros |
| Earnings Call Timestamp End | 1,774,989,000 |
| Earnings Call Timestamp Start | 1,774,989,000 |
| Earnings Timestamp | 1,774,987,200 |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda | -121,832,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.583 |
| Enterprise Value | 1,045,662,528 |
| Eps Current Year | -1.54 |
| Eps Forward | 1.37667 |
| Eps Trailing Twelve Months | -0.08 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.376 |
| Fifty Day Average Change | 2.0639992 |
| Fifty Day Average Change Percent | 0.18143453 |
| Fifty Two Week Change Percent | 100.59702 |
| Fifty Two Week High | 17.65 |
| Fifty Two Week High Change | -4.21 |
| Fifty Two Week High Change Percent | -0.23852693 |
| Fifty Two Week Low | 2.95 |
| Fifty Two Week Low Change | 10.49 |
| Fifty Two Week Low Change Percent | 3.555932 |
| Fifty Two Week Range | 2.95 - 17.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,255,008,600,000 |
| Float Shares | 69,284,075 |
| Forward Eps | 1.37667 |
| Forward P E | 9.762688 |
| Free Cashflow | 170,337,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 175 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -35,629,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02803 |
| Held Percent Institutions | 0.46683 |
| Implied Shares Outstanding | 71,996,171 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. |
| Long Name | Omeros Corporation |
| Market | us_market |
| Market Cap | 967,628,480 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_32388 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -4,808,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 967,628,538 |
| Number Of Analyst Opinions | 2 |
| Open | 12.6 |
| Operating Cashflow | -116,094,000 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.81 |
| Phone | 206 676 5000 |
| Post Market Change | -0.2265997 |
| Post Market Change Percent | -1.6860096 |
| Post Market Price | 13.2134 |
| Post Market Time | 1,776,469,940 |
| Previous Close | 12.54 |
| Price Eps Current Year | -8.727273 |
| Price Hint | 2 |
| Price To Book | -7.9479594 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.341 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.9 |
| Regular Market Change Percent | 7.17703 |
| Regular Market Day High | 13.455 |
| Regular Market Day Low | 12.46 |
| Regular Market Day Range | 12.46 - 13.455 |
| Regular Market Open | 12.6 |
| Regular Market Previous Close | 12.54 |
| Regular Market Price | 13.44 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,948,346 |
| Return On Assets | -0.25467 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 71,996,171 |
| Shares Percent Shares Out | 0.23709999 |
| Shares Short | 17,069,802 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 17,289,620 |
| Short Name | Omeros Corporation |
| Short Percent Of Float | 0.2459 |
| Short Ratio | 19.97 |
| Source Interval | 15 |
| State | WA |
| Symbol | OMER |
| Target High Price | 40.0 |
| Target Low Price | 36.0 |
| Target Mean Price | 38.0 |
| Target Median Price | 38.0 |
| Total Cash | 171,804,000 |
| Total Cash Per Share | 2.386 |
| Total Debt | 249,838,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.08 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.31035 |
| Two Hundred Day Average Change | 5.129649 |
| Two Hundred Day Average Change Percent | 0.6172603 |
| Type Disp | Equity |
| Volume | 1,948,346 |
| Website | https://www.omeros.com |
| Zip | 98,119 |